3/20
07:12 am
fold
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report [Yahoo! Finance]
Low
Report
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report [Yahoo! Finance]
3/20
07:00 am
fold
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
Low
Report
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
3/18
02:51 pm
fold
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target lowered by analysts at JPMorgan Chase & Co. from $21.00 to $19.00. They now have an "overweight" rating on the stock.
Low
Report
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target lowered by analysts at JPMorgan Chase & Co. from $21.00 to $19.00. They now have an "overweight" rating on the stock.
3/7
12:13 am
fold
Director Margaret Mcglynn Sells 15,000 Shares of Amicus Therapeutics Inc (FOLD) [Yahoo! Finance]
Low
Report
Director Margaret Mcglynn Sells 15,000 Shares of Amicus Therapeutics Inc (FOLD) [Yahoo! Finance]
3/2
09:33 am
fold
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]
Low
Report
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]
3/1
07:00 am
fold
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
Medium
Report
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
2/29
02:34 pm
fold
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $22.00 price target on the stock.
Low
Report
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $22.00 price target on the stock.
2/29
12:55 pm
fold
Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates [Yahoo! Finance]
Low
Report
Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates [Yahoo! Finance]
2/29
11:43 am
fold
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/29
08:14 am
fold
In Sickness. Men and the Culture of Caregiving Launches as Podcast Sharing Powerful Stories of Male Caregivers [Yahoo! Finance]
Medium
Report
In Sickness. Men and the Culture of Caregiving Launches as Podcast Sharing Powerful Stories of Male Caregivers [Yahoo! Finance]
2/28
07:48 am
fold
Amicus Therapeutics Inc (FOLD) Reports 21% Revenue Growth in 2023, Eyes Non-GAAP Profitability ... [Yahoo! Finance]
Medium
Report
Amicus Therapeutics Inc (FOLD) Reports 21% Revenue Growth in 2023, Eyes Non-GAAP Profitability ... [Yahoo! Finance]
2/28
07:10 am
fold
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates [Yahoo! Finance]
Medium
Report
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates [Yahoo! Finance]
2/28
07:00 am
fold
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
Medium
Report
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
2/15
07:00 am
fold
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
Medium
Report
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
2/14
04:58 pm
fold
Fabry Disease Treatment Market: Comprehensive Insights and Growth Projections for 2024-2030 [Yahoo! Finance]
Medium
Report
Fabry Disease Treatment Market: Comprehensive Insights and Growth Projections for 2024-2030 [Yahoo! Finance]
2/8
07:19 am
fold
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™ [Yahoo! Finance]
Low
Report
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™ [Yahoo! Finance]
2/8
07:00 am
fold
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
High
Report
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
2/1
07:11 am
fold
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024 [Yahoo! Finance]
Medium
Report
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024 [Yahoo! Finance]
2/1
07:00 am
fold
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
Medium
Report
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
1/26
06:36 pm
fold
Global Pompe Disease Drugs Market: USD 294.7 Million Growth Forecasted at a CAGR of 4.16% between 2024 to 2028 - Technavio [Yahoo! Finance]
Medium
Report
Global Pompe Disease Drugs Market: USD 294.7 Million Growth Forecasted at a CAGR of 4.16% between 2024 to 2028 - Technavio [Yahoo! Finance]
1/12
11:28 am
fold
Amicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Why [Yahoo! Finance]
Low
Report
Amicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Why [Yahoo! Finance]
1/8
11:16 am
fold
Amicus (FOLD) Issues Preliminary Revenue Results for FY23 [Yahoo! Finance]
Low
Report
Amicus (FOLD) Issues Preliminary Revenue Results for FY23 [Yahoo! Finance]
1/8
02:14 am
fold
Amicus Therapeutics sees 2023 revenue growth of 21% Y/Y; issues 2024 strategic outlook [Seeking Alpha]
Low
Report
Amicus Therapeutics sees 2023 revenue growth of 21% Y/Y; issues 2024 strategic outlook [Seeking Alpha]
1/7
04:15 pm
fold
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook [Yahoo! Finance]
Low
Report
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook [Yahoo! Finance]
1/7
04:00 pm
fold
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
Low
Report
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook